Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III or Stage IV Cancer of the Oropharynx, Hypopharynx, or Larynx

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00004227
Recruitment Status : Terminated
First Posted : January 27, 2003
Last Update Posted : February 6, 2014
National Cancer Institute (NCI)
Information provided by (Responsible Party):
University of Alabama at Birmingham

No Study Results Posted on for this Study
  Recruitment Status : Terminated
  Actual Primary Completion Date : March 2007
  Actual Study Completion Date : May 2008
Publications of Results:
Bonner JA, Harari PM, Giralt J, et al.: The relationship of cetuximab-induced rash and survival in patients with head and neck cancer treated with radiotherapy and cetuximab. [Abstract] Int J Radiat Oncol Biol Phys 63 (2 Suppl 1): A-120, S73, 2005.
Bonner JA, Girald J, Harari PM, et al.: Phase III evaluation of radiation with and without cetuximab for locoregionally advanced head and neck cancer. [Abstract] Int J Radiat Oncol Biol Phys 60 (1 Suppl 1): A-31, S147-8, 2004. Available online. Last accessed February 3, 2005.

Publications automatically indexed to this study by Identifier (NCT Number):